These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20208477)

  • 1. Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas.
    de Muga S; Hernández S; Agell L; Salido M; Juanpere N; Lorenzo M; Lorente JA; Serrano S; Lloreta J
    Mod Pathol; 2010 May; 23(5):703-12. PubMed ID: 20208477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients.
    Qi M; Yang X; Zhang F; Lin T; Sun X; Li Y; Yuan H; Ren Y; Zhang J; Qin X; Han B
    PLoS One; 2014; 9(2):e84959. PubMed ID: 24516518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN Loss in a Prostate Cancer Cohort From Jordan.
    Al Bashir S; Alzoubi A; Alfaqih MA; Kheirallah K; Smairat A; Haddad H; Al-Dwairy A; Fawwaz BAB; Alzoubi M; Trpkov K
    Appl Immunohistochem Mol Morphol; 2020; 28(5):389-394. PubMed ID: 30614821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.
    Murphy SJ; Karnes RJ; Kosari F; Castellar BE; Kipp BR; Johnson SH; Terra S; Harris FR; Halling GC; Klein JL; Nasir A; Bergstrahl E; Rangel LJ; Sukov WR; Vasmatzis G; Cheville JC
    Mod Pathol; 2016 Feb; 29(2):143-56. PubMed ID: 26612463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors.
    Freeman SS; Allen SW; Ganti R; Wu J; Ma J; Su X; Neale G; Dome JS; Daw NC; Khoury JD
    Cancer; 2008 Sep; 113(6):1453-61. PubMed ID: 18704985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
    Shah RB; Shore KT; Yoon J; Mendrinos S; McKenney JK; Tian W
    Prostate; 2019 Aug; 79(11):1267-1273. PubMed ID: 31111513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.
    Salmaninejad A; Ghadami S; Dizaji MZ; Golchehre Z; Estiar MA; Zamani MR; Ebrahimzadeh-Vesal R; Nowroozi MR; Shakoori A
    Clin Lab; 2015; 61(7):749-59. PubMed ID: 26299074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
    Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.
    Byun DS; Cho K; Ryu BK; Lee MG; Park JI; Chae KS; Kim HJ; Chi SG
    Int J Cancer; 2003 Apr; 104(3):318-27. PubMed ID: 12569555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas.
    Projetti F; Durand K; Chaunavel A; Léobon S; Lacorre S; Caire F; Bessède JP; Moreau JJ; Coulibaly B; Labrousse F
    Hum Pathol; 2013 Oct; 44(10):2116-25. PubMed ID: 23791006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa).
    Fu M; Zhang W; Shan L; Song J; Shang D; Ying J; Zhao J
    Virchows Arch; 2014 May; 464(5):575-81. PubMed ID: 24595526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.
    Trock BJ; Fedor H; Gurel B; Jenkins RB; Knudsen BS; Fine SW; Said JW; Carter HB; Lotan TL; De Marzo AM
    Mod Pathol; 2016 Jul; 29(7):764-71. PubMed ID: 27080984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
    Liang Z; Zeng X; Gao J; Wu S; Wang P; Shi X; Zhang J; Liu T
    BMC Cancer; 2008 Dec; 8():363. PubMed ID: 19061514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.
    Bhargava R; Gerald WL; Li AR; Pan Q; Lal P; Ladanyi M; Chen B
    Mod Pathol; 2005 Aug; 18(8):1027-33. PubMed ID: 15920544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours.
    Izycka-Swieszewska E; Brzeskwiniewicz M; Wozniak A; Drozynska E; Grajkowska W; Perek D; Balcerska A; Klepacka T; Limon J
    Folia Neuropathol; 2010; 48(4):238-45. PubMed ID: 21225506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.
    Cuzick J; Yang ZH; Fisher G; Tikishvili E; Stone S; Lanchbury JS; Camacho N; Merson S; Brewer D; Cooper CS; Clark J; Berney DM; Møller H; Scardino P; Sangale Z;
    Br J Cancer; 2013 Jun; 108(12):2582-9. PubMed ID: 23695019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
    Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
    Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
    Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
    J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
    Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
    Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer.
    Ach T; Zeitler K; Schwarz-Furlan S; Baader K; Agaimy A; Rohrmeier C; Zenk J; Gosau M; Reichert TE; Brockhoff G; Ettl T
    Virchows Arch; 2013 Jan; 462(1):65-72. PubMed ID: 23242174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.